Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 6/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.53 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407236 | 0.87 | PDE4A (0.55) | LMNAKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL12808163 | 0.86 | MAOB (0.66) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL1682158 | 0.86 | MAOB (0.66) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL10610437 | 0.85 | PDE4A (0.74) | LMNAKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL10610432 | 0.85 | PDE4A (0.74) | LMNAKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL25266006 | 0.84 | SLC5A1 (0.74) | LMNAKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL17523254 | 0.84 | PDE4A (0.55) | LMNAKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL30383068 | 0.84 | PDE4A (0.55) | LMNAKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL3673937 | 0.84 | SLC5A1 (0.66) | LMNAKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL31233231 | 0.84 | SLC5A1 (0.66) | LMNAKDM4EPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181293-B2 | Method for the synthesis of aspalathin and analogues thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2015-11-10 | — | — | US | disclosed |
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | ASPH, C9, ALDH3A1 | LMNA 3392/4885KDM4E 550/4885PDE4A 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.